Preclinical toxicology of large molecule drugs developed for cancer and other indications
Active Definitive Contract Awarded Last action
- Contract number
- 75N91022C00010
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,452,984
Award facts
- Contract value 37% obligated
-
- $4,538,201.00 Current, with exercised options
- $9,353,817.00 Potential, with all options
- Completion date 65% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $549,996 | |
| Exercise an Option | $10,000 | |
| Exercise an Option | $10,025 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $375,416 | |
| Exercise an Option | $300,728 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $676,819 | |
| Funding Only Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $309,267 | |
| Other Administrative Action | $470,733 | |
| Funding Only Action | $675,000 | |
| Original award | $75,000 |
Show all 15
About this award
The National Cancer Institute awarded a $9.35 million definitive contract to IIT Research Institute for preclinical toxicology of large molecule drugs developed for cancer and other indications on April 1, 2022, under cost-plus-fixed-fee pricing with no set-aside.
The originating solicitation addresses preclinical toxicology studies supporting investigational new drug development, aligned with Executive Order 14398 priorities. Place of performance is Chicago, IL. The contract runs through March 31, 2029.
IIT Research Institute is a non-profit contract research organization and wholly-owned subsidiary of Illinois Institute of Technology, operating exclusively as a prime contractor on federal preclinical drug development and toxicology research services to the National Institutes of Health ecosystem. The organization conducts Good Laboratory Practice and non-GLP toxicology studies in rodent and canine models, dose range-finding evaluations, pharmacokinetic analyses, and safety assessments for small molecule and biologic drug candidates.
Service Contract Inventory reporting for this contract shows FY2025 labor activity of 0.2 FTEs with no subcontractor involvement; the prime self-performed all reported work. Prior-year invoiced activity included $164 thousand in FY2023 across 18 contractor hours, reflecting periodic study milestones rather than continuous staffing. This contract represents one ordering vehicle within IIT Research Institute's broader $149.995 million multiple-award PREVENT Cancer Preclinical Drug Development Program IDIQ with NCI, which covers preclinical efficacy evaluation, analytical testing, process development, and toxicological testing of cancer preventive agents.
Quick answers
Who was awarded contract 75N91022C00010?
75N91022C00010 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on April 1, 2022.
How much is contract 75N91022C00010 worth?
The government has obligated $3,452,984 on 75N91022C00010. Its current value, with exercised options, is $4,538,201. Its potential value, with all options, is $9,353,817.
Was contract 75N91022C00010 competed?
The extent of competition for 75N91022C00010 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award